Targeting HIF-1 alpha Function in Cancer through the Chaperone Action of NQO1: Implications of Genetic Diversity of NQO1
MetadatosAfficher la notice complète
AuteurSalido, Eduardo; Palomino Morales, Rogelio Jesús; Pacheco García, Juan Luis; Pey Rodríguez, Ángel Luis
HIF-1alphaNQO1HypoxiaAngiogenesisCancerProtein: protein interactionsLigand bindingProteasomal degradationGenetic variability
Salido, E... [et al.]. Targeting HIF-1alpha Function in Cancer through the Chaperone Action of NQO1: Implications of Genetic Diversity of NQO1. J. Pers. Med. 2022, 12, 747. [https://doi.org/10.3390/jpm12050747]
PatrocinadorERDF/Spanish Ministry of Science, Innovation and Universities-State Research Agency RTI2018-096246-B-I00 PID2019-110900GBI00 SAF2015-69796; Junta de Andalucia P18-RT-2413; Government of AragonFEDER E35-20R
HIF-1 alpha is a master regulator of oxygen homeostasis involved in different stages of cancer development. Thus, HIF-1 alpha inhibition represents an interesting target for anti-cancer therapy. It was recently shown that the HIF-1 alpha interaction with NQO1 inhibits proteasomal degradation of the former, thus suggesting that targeting the stability and/or function of NQO1 could lead to the destabilization of HIF-1 alpha as a therapeutic approach. Since the molecular interactions of NQO1 with HIF-1 alpha are beginning to be unraveled, in this review we discuss: (1) Structure-function relationships of HIF-1 alpha; (2) our current knowledge on the intracellular functions and stability of NQO1; (3) the pharmacological modulation of NQO1 by small ligands regarding function and stability; (4) the potential effects of genetic variability of NQO1 in HIF-1 alpha levels and function; (5) the molecular determinants of NQO1 as a chaperone of many different proteins including cancer-associated factors such as HIF-1 alpha, p53 and p73 alpha. This knowledge is then further discussed in the context of potentially targeting the intracellular stability of HIF-1 alpha by acting on its chaperone, NQO1. This could result in novel anti-cancer therapies, always considering that the substantial genetic variability in NQO1 would likely result in different phenotypic responses among individuals.